Clinical, laboratory, and autopsy findings support an association between coronavirus
disease-2019 (COVID-19) and thromboembolic disease. Acute COVID-19 infection is …

Infection with the SARS-CoV-2 virus, resulting in COVID-19 disease, has presented a
unique scenario associated with high rates of thrombosis. The risk of venous thrombosis is …

Objective To evaluate the effects of therapeutic heparin compared with prophylactic heparin
among moderately ill patients with covid-19 admitted to hospital wards. Design Randomised …

Background Prior studies of therapeutic-dose anticoagulation in patients with COVID-19
have reported conflicting results. Objectives We sought to determine the safety and …

Background Pulmonary endothelial injury and microcirculatory thromboses likely contribute
to hypoxemic respiratory failure, the most common cause of death, in patients with COVID …

An important component of severe COVID-19 disease is virus-induced endothelilitis. This
leads to disruption of normal endothelial function, initiating a state of failing normal clotting …

Early in the coronavirus disease 2019 (COVID-19) pandemic, global governing bodies
prioritized transmissibility-based precautions and hospital capacity as the foundation for …

Coronavirus disease 2019 (COVID‐19) is associated with a hypercoagulable state. It has
been hypothesized that higher‐dose anticoagulation, including therapeutic‐dose and …

Abstract Coronavirus disease 2019 (COVID-19) has emerged as a pandemic at the end of
2019 and continues to exert an unfavorable worldwide health impact on a large proportion …

Objective To assess the benefits and harms of different types and doses of anticoagulant
drugs for the prevention of venous thromboembolism in patients who are acutely ill and …